Access this article Similar content being viewed by others References Cooper AJ, Gupta SR, Moustafa AF, Chao AM
While most clinicians focus on weight loss and glucose lowering, new data on GLP-1 microbiome effects suggest something deeper may be happening in the gut
Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as a new class of drugs designed to treat patients with type 2 diabetes (T2D), but have also been shown to be protective against HF-related events and CV mortality
Studies revealed that insulin has a more substantial effect on the survival of cancer cells, while IGF-1 was better in the cell cycle and proliferation (Cai W
Follicles in the stained sections were counted according to the method described by Zhuang et al
So its left to nutritionists to pay even closer attention to risk factors and side effects for any clients using compounded GLP-1 treatments